WAYNE, Pa., March 9, 2015 /PRNewswire/ -- Ryan &
Maniskas, LLP is investigating potential claims against the board
of directors of Pharmacyclics Inc. ("Pharmacyclics Inc." or the
"Company") (NASDAQ: PCYC) concerning possible breaches of fiduciary
duty and other violations of law related to the Company's efforts
to sell the Company to AbbVie Inc. ("AbbVie") in a transaction
valued at approximately $21
billion.
If you own shares of Pharmacyclics and would like to learn more
about this class action or if you wish to discuss these matters and
have any questions concerning this announcement or your rights,
contact Richard A. Maniskas, Esquire
toll-free at (877) 316-3218 or to sign up online, visit:
www.rmclasslaw.com/cases/pcyc. You may also email Mr. Maniskas at
rmaniskas@rmclasslaw.com.
Under the terms of the agreement, shareholders of Pharmacyclics
will receive $261.25 per share,
consisting of cash and AbbVie common stock. Pharmacyclics'
stockholders will be permitted to elect cash, AbbVie common stock
or a combination, subject to proration. The aggregate
consideration will consist of approximately 58% cash and 42% AbbVie
common stock.
Our investigation concerns possible breaches of fiduciary duty
and other violations of state law by the Board of Directors of
Pharmacyclics for not acting in the Company's shareholders' best
interests in connection with the sale process.
Ryan & Maniskas, LLP is a national shareholder litigation
firm. Ryan & Maniskas, LLP is devoted to protecting the
interests of individual and institutional investors in shareholder
actions in state and federal courts nationwide. To learn more
about the class action process, please visit:
www.rmclasslaw.com.
CONTACT: Ryan & Maniskas, LLP
Richard A. Maniskas, Esquire
995 Old
Eagle School Rd., Suite 311
Wayne, PA
19087
877-316-3218
www.rmclasslaw.com/cases/pcyc
rmaniskas@rmclasslaw.com
Photo -
http://photos.prnewswire.com/prnh/20121112/MM11729LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ryan--maniskas-llp-announces-investigation-of-pharmacyclics-inc-300047366.html
SOURCE Ryan & Maniskas, LLP